Express Scripts Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (30)

Latest Posts

About This Stock More About This Stock
A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks
Article By: Sweta Killa
Friday, May 18, 2018 9:08 PM EDT
Investors are mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms.
In this article: EA, AAPL, ADBE, AMZN, MSFT, NFLX, FB, GOOGL, TWX, UNH, ANTM, CVS, ESRX, GRBK, TUSK, GHDX, ZGNX, RTRX, PCRX, PTCT, CORI, SBBP
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Deal Dead? Express Scripts Has 28% Upside To Cigna Buyout Offer Price
Article By: Chad Brand
Wednesday, April 11, 2018 11:07 AM EDT
With ESRX having 28% upside if the deal is allowed, it might seem like a no-brainer risk/reward situation to go long the stock.
In this article: ESRX Also: T, TWX, CI, CVS, AET
Read
Morgan Stanley: 5 Top Takeover Targets For 2018
Article By: TipRanks
Sunday, February 4, 2018 12:50 PM EDT
Lucky investors can see share prices soar when a takeover deal is announced, meaning that there is big value in identifying takeover targets correctly. Four of the five stocks below boast a ‘Strong Buy’ analyst consensus rating.
In this article: DPZ, GPK, GRA, ESRX, PF
Read
Express Scripts Sells Unit With Ties To Mallinckrodt's Acthar
Article By: Shock Exchange
Wednesday, November 29, 2017 7:09 PM EDT
ESRX sold a sold a unit with ties to MNK's Acthar. It could be an attempt by ESRX to distance itself from the high-priced drug. It could hasten Acthar's demise.
In this article: ESRX, MNK
Read

PARTNER HEADLINES

Latest Tweets for $ESRX

No tweets yet!